Synopsis
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 312.4 g/mol |
---|---|
Molecular Formula | C17H20N4S |
XLogP3 | 2.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 1 |
Exact Mass | 312.14086783 g/mol |
Monoisotopic Mass | 312.14086783 g/mol |
Topological Polar Surface Area | 56.2 A^2 |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 543 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 8 | |
---|---|
Drug Name | Olanzapine |
PubMed Health | Olanzapine |
Drug Classes | Antipsychotic |
Drug Label | Olanzapine is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresponds to a... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet; Injectable; Tablet, orally disintegrating |
Route | oral; Oral; Intramuscular |
Strength | 2.5mg; 10mg/vial; 7.5mg; 15mg; 5mg; 10mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharms; Apotex; Aurobindo Pharma; Sun Pharm Inds; Torrent Pharms; Barr Labs; Sandoz; Par Pharm; Roxane; Teva Pharms; Macleods Pharms; Jubilant Generics; Luitpold; Dr Reddys Labs; Orchid Hlthcare; Mylan |
2 of 8 | |
---|---|
Drug Name | Symbyax |
PubMed Health | Olanzapine/Fluoxetine (By mouth) |
Drug Classes | Antidepressant, Antipsychotic |
Active Ingredient | Fluoxetine hydrochloride; olanzapine |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg base; eq 6mg base; eq 12mg base; eq 3mg base; eq 25mg base |
Market Status | Prescription |
Company | Lilly |
3 of 8 | |
---|---|
Drug Name | Zyprexa |
Drug Label | ZYPREXA (olanzapine) is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresp... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet; Injectable |
Route | Oral; Intramuscular |
Strength | 2.5mg; 10mg/vial; 7.5mg; 15mg; 5mg; 10mg; 20mg |
Market Status | Prescription |
Company | Lilly |
4 of 8 | |
---|---|
Drug Name | Zyprexa zydis |
Drug Label | ZYPREXA (olanzapine) is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresp... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet, orally disintegrating |
Route | Oral |
Strength | 15mg; 5mg; 10mg; 20mg |
Market Status | Prescription |
Company | Lilly |
5 of 8 | |
---|---|
Drug Name | Olanzapine |
PubMed Health | Olanzapine |
Drug Classes | Antipsychotic |
Drug Label | Olanzapine is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresponds to a... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet; Injectable; Tablet, orally disintegrating |
Route | oral; Oral; Intramuscular |
Strength | 2.5mg; 10mg/vial; 7.5mg; 15mg; 5mg; 10mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharms; Apotex; Aurobindo Pharma; Sun Pharm Inds; Torrent Pharms; Barr Labs; Sandoz; Par Pharm; Roxane; Teva Pharms; Macleods Pharms; Jubilant Generics; Luitpold; Dr Reddys Labs; Orchid Hlthcare; Mylan |
6 of 8 | |
---|---|
Drug Name | Symbyax |
PubMed Health | Olanzapine/Fluoxetine (By mouth) |
Drug Classes | Antidepressant, Antipsychotic |
Active Ingredient | Fluoxetine hydrochloride; olanzapine |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg base; eq 6mg base; eq 12mg base; eq 3mg base; eq 25mg base |
Market Status | Prescription |
Company | Lilly |
7 of 8 | |
---|---|
Drug Name | Zyprexa |
Drug Label | ZYPREXA (olanzapine) is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresp... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet; Injectable |
Route | Oral; Intramuscular |
Strength | 2.5mg; 10mg/vial; 7.5mg; 15mg; 5mg; 10mg; 20mg |
Market Status | Prescription |
Company | Lilly |
8 of 8 | |
---|---|
Drug Name | Zyprexa zydis |
Drug Label | ZYPREXA (olanzapine) is an atypical antipsychotic that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b] [1,5]benzodiazepine. The molecular formula is C17H20N4S, which corresp... |
Active Ingredient | Olanzapine |
Dosage Form | Tablet, orally disintegrating |
Route | Oral |
Strength | 15mg; 5mg; 10mg; 20mg |
Market Status | Prescription |
Company | Lilly |
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-03-03
Pay. Date : 2013-01-23
DMF Number : 26694
Submission : 2013-01-24
Status : Active
Type : II
NDC Package Code : 64567-0017
Start Marketing Date : 2013-01-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2020-11-13
Registration Number : 20201113-209-J-568
Manufacturer Name : INKE SA
Manufacturer Address : C/Argent, 1. Area Industrial del Llobregat, 08755 Castellbisbal (Barcelona), Spain
Available Reg Filing : ASMF |
Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19282
Submission : 2006-03-24
Status : Active
Type : II
Certificate Number : R1-CEP 2012-190 - Rev 01
Issue Date : 2021-09-07
Type : Chemical
Substance Number : 2258
Status : Valid
Date of Issue : 2022-07-28
Valid Till : 2025-06-16
Written Confirmation Number : WC-0036
Address of the Firm :
NDC Package Code : 58032-0122
Start Marketing Date : 2017-12-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Samil Pharmaceutical Co., Ltd.
Registration Date : 2022-08-22
Registration Number : 20220822-209-J-1347
Manufacturer Name : Neuland Laboratories Ltd
Manufacturer Address : Unit-I, Survey No: 347, 473, 474, 490/2 Veerabhadraswamy temple road,Bonthapally Village, Gummadidala Mandal,Sangareddy District - 502313, Telangana, India
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39150
Submission : 2023-12-05
Status : Active
Type : II
Certificate Number : R1-CEP 2017-020 - Rev 00
Issue Date : 2023-05-22
Type : Chemical
Substance Number : 2258
Status : Valid
Date of Issue : 2019-09-27
Valid Till : 2022-07-28
Written Confirmation Number : WC-0186
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-03
Pay. Date : 2013-09-23
DMF Number : 26763
Submission : 2012-12-28
Status : Active
Type : II
Certificate Number : R1-CEP 2012-406 - Rev 01
Issue Date : 2023-07-20
Type : Chemical
Substance Number : 2258
Status : Valid
NDC Package Code : 49587-103
Start Marketing Date : 2014-12-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Complete
Rev. Date : 2014-03-03
Pay. Date : 2013-01-23
DMF Number : 26694
Submission : 2013-01-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19282
Submission : 2006-03-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15052
Submission : 2000-09-18
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-01-24
Pay. Date : 2013-12-10
DMF Number : 20591
Submission : 2007-06-11
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-23
Pay. Date : 2012-12-17
DMF Number : 20990
Submission : 2007-10-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20354
Submission : 2007-03-16
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-07-13
Pay. Date : 2021-07-09
DMF Number : 18260
Submission : 2005-04-08
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-02-18
Pay. Date : 2014-02-10
DMF Number : 20218
Submission : 2007-01-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18108
Submission : 2005-02-07
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18867
Submission : 2005-10-14
Status : Inactive
Type : II
Certificate Number : R1-CEP 2012-190 - Rev 01
Status : Valid
Issue Date : 2021-09-07
Type : Chemical
Substance Number : 2258
Certificate Number : R0-CEP 2015-058 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2016-06-17
Type : Chemical
Substance Number : 2258
Certificate Number : R1-CEP 2012-215 - Rev 00
Status : Valid
Issue Date : 2019-01-29
Type : Chemical
Substance Number : 2258
Certificate Number : R0-CEP 2018-111 - Rev 00
Status : Valid
Issue Date : 2020-06-10
Type : Chemical
Substance Number : 2258
Certificate Number : R0-CEP 2012-402 - Rev 00
Status : Expired
Issue Date : 2015-01-23
Type : Chemical
Substance Number : 2258
Certificate Number : R1-CEP 2014-003 - Rev 00
Status : Valid
Issue Date : 2020-02-21
Type : Chemical
Substance Number : 2258
Certificate Number : R0-CEP 2012-208 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2014-07-15
Type : Chemical
Substance Number : 2258
Certificate Number : R1-CEP 2012-191 - Rev 01
Status : Valid
Issue Date : 2021-09-16
Type : Chemical
Substance Number : 2258
Certificate Number : R1-CEP 2015-238 - Rev 00
Status : Valid
Issue Date : 2022-03-03
Type : Chemical
Substance Number : 2258
Certificate Number : R1-CEP 2012-300 - Rev 01
Status : Valid
Issue Date : 2021-02-09
Type : Chemical
Substance Number : 2258
Registration Number : 227MF10030
Registrant's Address : 2477, Nambusunhwan-ro Seocho-gu, Seoul, Republic of Korea
Initial Date of Registration : 2015-01-23
Latest Date of Registration : 2015-11-11
Registration Number : 227MF10066
Registrant's Address : 1062-8 Honjo, Nishikata-cho, Tochigi City, Tochigi Prefecture
Initial Date of Registration : 2015-03-06
Latest Date of Registration : 2015-11-11
Registration Number : 227MF10033
Registrant's Address : No. 9 Dongjin Road, Economic & Technical Development Zone, Lianyungang, Jiangsu 22206...
Initial Date of Registration : 2015-01-23
Latest Date of Registration : 2015-01-23
Registration Number : 227MF10065
Registrant's Address : 7-2-A2, Hetero Corporate, Industrial Estates, Sanath Nagar, Hyderabad-500 018, Telang...
Initial Date of Registration : 2015-03-06
Latest Date of Registration : 2015-11-19
Registration Number : 227MF10037
Registrant's Address : 1A, Sector 16A, Noida 201 301, Uttar Pradesh, India
Initial Date of Registration : 2015-02-04
Latest Date of Registration : 2015-02-04
Registration Number : 227MF10016
Registrant's Address : 1-10-11 Nihonbashi Horidomecho, Chuo-ku, Tokyo
Initial Date of Registration : 2015-01-05
Latest Date of Registration : 2015-11-17
Registration Number : 227MF10025
Registrant's Address : 2-36-1 Kanda Jinbocho, Chiyoda-ku, Tokyo
Initial Date of Registration : 2015-01-23
Latest Date of Registration : 2015-11-17
Olanzapine (for manufacturing purposes only)
Registration Number : 226MF10142
Registrant's Address : 2-3-5 Shimookui, Toyama City, Toyama Prefecture
Initial Date of Registration : 2014-07-31
Latest Date of Registration : 2015-05-14
Registration Number : 227MF10046
Registrant's Address : 6-11-24 Tsudanuma, Narashino City, Chiba Prefecture
Initial Date of Registration : 2015-02-09
Latest Date of Registration : 2015-11-11
Registration Number : 226MF10039
Registrant's Address : 1133 Oe, Imizu City, Toyama Prefecture
Initial Date of Registration : 2014-02-19
Latest Date of Registration : 2015-11-17
Date of Issue : 2022-07-28
Valid Till : 2025-06-16
Written Confirmation Number : WC-0036
Address of the Firm : Sy. No. 347,473,474, 490/2 Bonthapally village, Veerabhadraswamy Temple Road, Ji...
Date of Issue : 2022-06-06
Valid Till : 2025-06-10
Written Confirmation Number : WC-0017
Address of the Firm : Unit No. VIII, Sy. No. 10 & 13, Gaddapotharam Village, I,D.A. Kazipally, Jinnara...
Date of Issue : 2022-09-01
Valid Till : 2025-07-02
Written Confirmation Number : WC-0074
Address of the Firm : 294, GIDC Estate, Ankleshwar-393 002, Bharuch, Gujarat, India
Date of Issue : 2022-02-02
Valid Till : 2024-06-07
Written Confirmation Number : WC-0317
Address of the Firm : Plot.No 43 & 44, IDA Phase-II, Pashamylaram, Patancheru Mandal, Medak Disctrict,...
Date of Issue : 2022-07-04
Valid Till : 2025-07-03
Written Confirmation Number : WC-0040
Address of the Firm : Unit-I, Survey No.213, 214 & 255, Bonthapally Village, Jinnaram Mandal, Medak ...
Date of Issue : 2019-09-27
Valid Till : 2022-07-28
Written Confirmation Number : WC-0186
Address of the Firm : Sy. No. 10/G-1, Gaddapotharam Village, Jinnaram Mandal, Medak Dist, AP
Date of Issue : 2019-11-28
Valid Till : 2022-07-02
Written Confirmation Number : WC-0079
Address of the Firm : Plot No.2209, GIDC, Industrial Estate, At & Post Sarigam, Tal-Umbergaon, Valsad-...
Date of Issue : 2022-05-02
Valid Till : 2025-07-25
Written Confirmation Number : WC-0027
Address of the Firm : Unit-II, Survey No.14, IDA Gaddapotharam (Village), Kazipally, Jinnaram (Mandal)...
Date of Issue : 2022-06-08
Valid Till : 2025-07-25
Written Confirmation Number : WC-0159
Address of the Firm : A-7/A-8, MIDC, Ahmednagar-414 111, Maharashtra State
Date of Issue : 2022-06-08
Valid Till : 2025-06-02
Written Confirmation Number : WC-0011
Address of the Firm : Village toansa, P.O Rail Majra, District S.B.S nagar nawanshahar-144533 Punjab I...
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2020-11-13
Registration Number : 20201113-209-J-568
Manufacturer Name : INKE SA
Manufacturer Address : C/Argent, 1. Area Industrial del Llobregat, 08755 Castellbisbal (Barcelona), Spain
Registrant Name : Samil Pharmaceutical Co., Ltd.
Registration Date : 2022-08-22
Registration Number : 20220822-209-J-1347
Manufacturer Name : Neuland Laboratories Ltd
Manufacturer Address : Unit-I, Survey No: 347, 473, 474, 490/2 Veerabhadraswamy temple road,Bonthapally Vill...
Registrant Name : Boryeong Co., Ltd.
Registration Date : 2022-08-04
Registration Number : 20220804-209-J-1338
Manufacturer Name : Eli Lilly Kinsale Limited
Manufacturer Address : Dunderrow, Kinsale, Co. Cork, Ireland
Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2021-05-18
Registration Number : 20210518-209-J-928
Manufacturer Name : Hetero Drugs Limited Unit I
Manufacturer Address : Survey. No. 213, 214 and 255, Bonthapally Village, Gummadidala Mandal, Sangareddy Dis...
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2022-01-10
Registration Number : 20220110-209-J-1201
Manufacturer Name : Jubilant Generics Limited
Manufacturer Address : Plot No. 18, 56, 57 & 58, KIADB Industrial Area, Nanjangud-571 302, Mysore District, ...
Registrant Name : Lee Sung International Co., Ltd.
Registration Date : 2021-04-09
Registration Number : 20210409-209-J-926
Manufacturer Name : Nosch Labs Private Limited U...
Manufacturer Address : Sy.No.14, Gaddapotharam Village, IDA, Kazipally, Jinnaram Mandal, Sangareddy District...
Registrant Name : Pharmasolution Co., Ltd.
Registration Date : 2024-08-26
Registration Number : 20210721-209-J-1041(1)
Manufacturer Name : Solara Active Pharma Science...
Manufacturer Address : A1/B, SIPCOT Industrial Complex, Kudikadu, Cuddalore- 607 005, India
Registrant Name : Insung Trading Co., Ltd.
Registration Date : 2021-07-21
Registration Number : 20210721-209-J-1041
Manufacturer Name : Solara Active Pharma Science...
Manufacturer Address : A1/B, SIPCOT Industrial Complex, Kudikadu, Cuddalore- 607 005, India
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2020-06-11
Registration Number : 20200611-209-J-402
Manufacturer Name : Teva API India Private Limit...
Manufacturer Address : Plot No, A-2, A-2/1, A-2/2, UPSIDC Industrial Area, Gajraula, Distt. Amroha (UP) Indi...
Registrant Name : Sangjin Corporation
Registration Date : 2021-07-06
Registration Number : 20210706-209-J-1029
Manufacturer Name : Laxai Life Sciences Private ...
Manufacturer Address : Plot No. 9/A, Phase-III, Jeedimetla, Quthbullapur, Medchal-Malkajgiri, District-50005...
NDC Package Code : 64567-0017
Start Marketing Date : 2013-01-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 58032-0122
Start Marketing Date : 2017-12-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49867-0056
Start Marketing Date : 2010-11-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 59651-006
Start Marketing Date : 2023-12-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65862-546
Start Marketing Date : 2023-11-15
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 12651-125
Start Marketing Date : 2023-10-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 53104-7534
Start Marketing Date : 2016-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49587-103
Start Marketing Date : 2014-12-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65372-1183
Start Marketing Date : 2016-02-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 72643-023
Start Marketing Date : 2020-05-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
About the Company : Nortec QuÃmica stands as the largest manufacturer of Active Pharmaceutical Ingredients (IFAs) in Latin America, embarking on its mission to ensure the availability of quality medi...
About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...
About the Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering g...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.
About the Company : Synnat Pharma is a fast-growing pharmaceutical company dedicated to the identification, development, production and distribution of potent phytochemicals and botanical extracts. AP...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : Established in 1984, Neuland Laboratories Limited is a publicly listed company headquartered in Hyderabad, India. The company provides solutions across the entire spectrum of the p...
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
About the Company : Octavius Pharma is a global leader in Directly Compressible Granules with over 40 years of experience in Formulation development, manufacturing and commercialization. It offers a w...
About the Company : Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not on...
About the Company : Enaltec Labs was established in 2006 by a group of young & experienced professionals with the specific objective to develop & produce complex, small volume, technology driven produ...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
TEV-‘749 is being developed as a once-monthly subcutaneous LAI of olanzapine with the use of SteadyTeq™ technology, a copolymer technology for the treatment of adults with schizophrenia.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Brand Name: TEV-‘749
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: MedinCell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2024
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : MedinCell
Deal Size : Not Applicable
Deal Type : Not Applicable
Teva Updates on Pivotal Phase 3 Trial of Olanzapine Long-Acting Injectable
Details : TEV-‘749 is being developed as a once-monthly subcutaneous LAI of olanzapine with the use of SteadyTeq™ technology, a copolymer technology for the treatment of adults with schizophrenia.
Brand Name : TEV-‘749
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 05, 2024
Details:
TEV-‘749 is being developed as a once-monthly subcutaneous long-acting injection of olanzapine with the use of SteadyTeq™ technology, a copolymer technology for the treatment of adults with schizophrenia.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Brand Name: TEV-‘749
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: MedinCell
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : MedinCell
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TEV-‘749 is being developed as a once-monthly subcutaneous long-acting injection of olanzapine with the use of SteadyTeq™ technology, a copolymer technology for the treatment of adults with schizophrenia.
Brand Name : TEV-‘749
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 08, 2024
Details:
TEV-44749 (olanzapine) is a novel D2/5-HT2 receptor inhibitor which is under phase 3 clinical development for the treatment of patients with Schizophrenia.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Brand Name: TEV-44749
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TEV-44749 (olanzapine) is a novel D2/5-HT2 receptor inhibitor which is under phase 3 clinical development for the treatment of patients with Schizophrenia.
Brand Name : TEV-44749
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 09, 2024
Details:
Lybalvi (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug. It is approved by USFDA for treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder.
Lead Product(s): Olanzapine,Samidorphan L-Malate
Therapeutic Area: Psychiatry/Psychology Brand Name: Lybalvi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Lead Product(s) : Olanzapine,Samidorphan L-Malate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lybalvi (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug. It is approved by USFDA for treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder.
Brand Name : Lybalvi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 03, 2024
Details:
The collaboration aims to co-develop and co-commercialize asset TEV’574, a novel anti-TL1A therapy, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Brand Name: TEV-‘749
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Sanofi
Deal Size: $1,500.0 million Upfront Cash: $500.0 million
Deal Type: Collaboration November 30, 2023
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Sanofi
Deal Size : $1,500.0 million
Deal Type : Collaboration
Details : The collaboration aims to co-develop and co-commercialize asset TEV’574, a novel anti-TL1A therapy, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
Brand Name : TEV-‘749
Molecule Type : Small molecule
Upfront Cash : $500.0 million
November 30, 2023
Details:
The collaboration aims to accelerate the clinical research program for Teva’s TEV-‘749 (olanzapine), a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Brand Name: TEV-‘749
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Royalty Pharma
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 13, 2023
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : $125.0 million
Deal Type : Collaboration
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
Details : The collaboration aims to accelerate the clinical research program for Teva’s TEV-‘749 (olanzapine), a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizoph...
Brand Name : TEV-‘749
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 13, 2023
Details:
The proceeds from the new bonds will be used to finance the acquisition of the worldwide commercial rights for Zyprexa (olanzapine), an antipsychotic medication, from Eli Lilly and Company.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Brand Name: Zyprexa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $825.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 28, 2023
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $825.9 million
Deal Type : Private Placement
Cheplapharm Places Notes in A Volume of €750m in Challenging Market Environment
Details : The proceeds from the new bonds will be used to finance the acquisition of the worldwide commercial rights for Zyprexa (olanzapine), an antipsychotic medication, from Eli Lilly and Company.
Brand Name : Zyprexa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 28, 2023
Details:
Olanzapine is an atypical antipsychotic that exerts its action primarily on dopamine and serotonin receptors. It works on dopamine D2 receptors in the mesolimbic pathway as an antagonist, blocking dopamine from potential action at the post-synaptic receptor.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Brand Name: Olanzapine-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2023
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Olanzapine is an atypical antipsychotic that exerts its action primarily on dopamine and serotonin receptors. It works on dopamine D2 receptors in the mesolimbic pathway as an antagonist, blocking dopamine from potential action at the post-synaptic recep...
Brand Name : Olanzapine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 11, 2023
Details:
mdc-TJK (olanzapine) is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. It works on dopamine D2 receptors in the mesolimbic pathway as an antagonist, blocking dopamine from potential action at the post-synaptic receptor.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Brand Name: TV-44749
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : mdc-TJK (olanzapine) is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. It works on dopamine D2 receptors in the mesolimbic pathway as an antagonist, blocking dopamine from potential action at the post-synaptic ...
Brand Name : TV-44749
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 24, 2023
Details:
The Phase 3 study will assess the efficacy and safety of potentially the first subcutaneous long-acting Injectable (LAI) formulation of mdc-TJK (olanzapine) for the treatment of patients with schizophrenia.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Brand Name: mdc-TJK
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 29, 2022
Lead Product(s) : Olanzapine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The Phase 3 study will assess the efficacy and safety of potentially the first subcutaneous long-acting Injectable (LAI) formulation of mdc-TJK (olanzapine) for the treatment of patients with schizophrenia.
Brand Name : mdc-TJK
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 29, 2022
3-Thiophene Carboxylic Acid-5-Methyl-2-[2(Nitrophe...
CAS Number : 72242-31-0
End Use API : Olanzapine
About The Company : Malladi Drugs & Pharmaceuticals Ltd was founded in 1980 by microbiologist Mr. M L N Sastry. Within a few years, Malladi established itself as a leader in manufa...
CAS Number : 1493-27-2
End Use API : Olanzapine
About The Company : Anupam Rasayan India Limited was started in 1976 and we are 36 years old. ISO 9001:2008 and ISO 14001:2004 certified chemical company with sound technology, en...
2-Amino 5-Methylthiophene-3-Carbonitrile
CAS Number : 138564-58-6
End Use API : Olanzapine
About The Company : Maruti Multichem Group, is a leading manufacturer and exporter of a wide range of Reactive Dyestuffs. Maruti Multichem Pvt Ltd is having highly motivated team o...
4-Amino-2-Methyl-10H-Thieno[2,3,b][1,5] Benzdiazep...
CAS Number : 138564-60-0
End Use API : Olanzapine
About The Company : Ramdev Chemicals Pvt. Ltd. is one of the fastest growing Active Pharmaceuticl Drugs, Drug Intermediates, Storage Fine Chemical Company in India which have speci...
2-Amino-5-Methylthiophene-3-Carbonitrile
CAS Number : CAS-138564-58-6
End Use API : Olanzapine
About The Company : We are Rampex Labs, a fully cGMP compliant pharmaceutical intermediates plant located in the outskirts of Hyderabad, India. Our company was founded in 2004 with...
5-Methyl-2-[(2-Nitrophenyl) Amino] Thiophene-3-Car...
CAS Number : CAS-138564-59-7
End Use API : Olanzapine
About The Company : We are Rampex Labs, a fully cGMP compliant pharmaceutical intermediates plant located in the outskirts of Hyderabad, India. Our company was founded in 2004 with...
4-Amino-2-Methyl-10H-Thieno [2, 3-B] [1, 5] Benzod...
CAS Number : CAS-138564-60-0
End Use API : Olanzapine
About The Company : We are Rampex Labs, a fully cGMP compliant pharmaceutical intermediates plant located in the outskirts of Hyderabad, India. Our company was founded in 2004 with...
2-(2- Aminophenylamino)-5-Methylthiophene-3-Caboni...
CAS Number : CAS-873895-41-1
End Use API : Olanzapine
About The Company : We are Rampex Labs, a fully cGMP compliant pharmaceutical intermediates plant located in the outskirts of Hyderabad, India. Our company was founded in 2004 with...
2-Methyl-10H-benzo[b]thio pheno[3,2- f]1,4-diazepi...
CAS Number : 138564-60-0
End Use API : Olanzapine
About The Company : Smilax Laboratories Limited is a research-driven, vertically integrated pharmaceutical company manufacturing Active Pharmaceutical Ingredients, API Intermediate...
2-Amino-5-Methyl-3-Thiophene Carbonitrile
CAS Number : 138564-58-6
End Use API : Olanzapine
About The Company : Suraj Laboratories Private Limited, established in 2021, is a pharmaceutical firm providing Contract Research and Manufacturing Services (CRAMS), Custom Synthes...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company :
Olanzapine/Fluoxetine HCl
Drug Cost (USD) : 87,783
Year : 2022
Prescribers : 37
Prescriptions : 181
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Olanzapine Pamoate
Drug Cost (USD) : 4,806,762
Year : 2022
Prescribers : 377
Prescriptions : 4405
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Olanzapine
Drug Cost (USD) : 3,550,664
Year : 2022
Prescribers : 277
Prescriptions : 2178
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Olanzapine/Fluoxetine HCl
Drug Cost (USD) : 112,208
Year : 2021
Prescribers : 43
Prescriptions : 213
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Olanzapine Pamoate
Drug Cost (USD) : 5,246,409
Year : 2021
Prescribers : 404
Prescriptions : 4785
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Olanzapine
Drug Cost (USD) : 3,792,411
Year : 2021
Prescribers : 292
Prescriptions : 2438
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Olanzapine
Drug Cost (USD) : 88,205,203
Year : 2020
Prescribers : 462889
Prescriptions : 3449920
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Olanzapine/Fluoxetine HCl
Drug Cost (USD) : 196,681
Year : 2020
Prescribers : 61
Prescriptions : 368
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Olanzapine Pamoate
Drug Cost (USD) : 5,449,379
Year : 2020
Prescribers : 432
Prescriptions : 4962
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Olanzapine
Drug Cost (USD) : 4,230,637
Year : 2020
Prescribers : 320
Prescriptions : 2913
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Tablet
Dosage Strength : 10mg
Price Per Pack (Euro) : 57.57
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
RX/OTC/DISCN : RX
Dosage Form : TABLET, ORALLY DISINTEGRATING;OR...
Dosage Strength : 5MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX
RX/OTC/DISCN :
Dosage Form : Tablets
Dosage Strength : 10 mg
Price Per Pack (Euro) : 33.5
Published in :
Country : Italy
RX/OTC/DISCN :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Tabl
Dosage Strength : 2.5mg
Price Per Pack (Euro) : 19.92
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Tabl
Dosage Strength : 5mg
Price Per Pack (Euro) : 32.73
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Tablet
Dosage Strength : 15mg
Price Per Pack (Euro) : 83.55
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
RX/OTC/DISCN : RX
Dosage Form : TABLET, ORALLY DISINTEGRATING;OR...
Dosage Strength : 10MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX
RX/OTC/DISCN : RX
Dosage Form : TABLET, ORALLY DISINTEGRATING;OR...
Dosage Strength : 15MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX
RX/OTC/DISCN : RX
Dosage Form : TABLET, ORALLY DISINTEGRATING;OR...
Dosage Strength : 20MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : RX
RX/OTC/DISCN :
Dosage Form : Orodispersible Tablets
Dosage Strength : 10 mg
Price Per Pack (Euro) : 33.5
Published in :
Country : Italy
RX/OTC/DISCN :
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 407
2019 Revenue in Millions : 419
Growth (%) : -3
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 430
2020 Revenue in Millions : 407
Growth (%) : 6
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 337
2021 Revenue in Millions : 430
Growth (%) : -22
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 1,695
2022 Revenue in Millions : 337
Growth (%) : 403
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 1,037
2014 Revenue in Millions : 940
Growth (%) : -9%
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : -13.20%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 725
2015 Revenue in Millions : 940
Growth (%) : -23
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 581
2016 Revenue in Millions : 725
Growth (%) : -20
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 471
2017 Revenue in Millions : 581
Growth (%) : -19%
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 419
2018 Revenue in Millions : 471
Growth (%) : -11
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
We have 14 companies offering Olanzapine
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?